Conexeu Sciences, Inc. engages in the development of regenerative biomaterials needed in wound care, dentistry, and aesthetics. The company is headquartered in Reno, Nevada. The company went IPO on 2026-05-21. The firm is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The firm is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The firm operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.
Forward revenue growth (NTM) 
